Effects of ethinylestradiol and levonorgestrel on morphology, ultrastructure and histoenzymatic activity of rat kidney

Physiological Research

Volumn 47, Issue 4, 1998, Pages 241-251

  Nowaczyk Dura, G ^a   Czekaj, P ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ethinylestradiol; Kidney; Levonorgestrel; Oral contraception; Rats

Indexed keywords

ACID PHOSPHATASE; ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ALKALINE PHOSPHATASE; ETHINYLESTRADIOL; GLUCOSE 6 PHOSPHATASE; LEVONORGESTREL; SUCCINATE DEHYDROGENASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ELECTRON TRANSPORT; ENZYME ACTIVITY; ESTROGEN THERAPY; FEMALE; GLUCONEOGENESIS; INTRAGASTRIC DRUG ADMINISTRATION; KIDNEY CORTEX; KIDNEY MEDULLA; MITOCHONDRIAL RESPIRATION; NONHUMAN; ORAL CONTRACEPTION; RAT;

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; ANIMALS; CA(2+) MG(2+)-ATPASE; CONTRACEPTIVES, ORAL, SYNTHETIC; EPITHELIAL CELLS; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; GLUCOSE-6-PHOSPHATASE; HISTOCYTOCHEMISTRY; KIDNEY; L-LACTATE DEHYDROGENASE; LEVONORGESTREL; MICROSCOPY, ELECTRON; NADPH-FERRIHEMOPROTEIN REDUCTASE; PROGESTERONE CONGENERS; RATS; RATS, WISTAR; SUCCINATE DEHYDROGENASE;

EID: 0031718901     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. APELO R., SUPLIDO A.: Clinical assesment of a new triphasic oral contraceptive. Clin. Ther. 8: 61-70, 1985.
2. BACIEWICZ A.: Oral contraceptive drug interaction. Ther. Drug Monit. 7: 26-35, 1985.
3. BALL P., KNUPPEN R.: Formation, metabolism and physiologic importance of catecholestrogens. Am. J. Obstet. Gynecol. 163: 2163-2170, 1990.
4. BONNAR J.: Coagulation effects of oral contraception. Am. J. Obstet. Gynecol. 157: 1042-1048, 1987.
5. BOSSARD R., STIEGER B., O'NEILL B., FRICKER G., MEIER P.: Ethinylestradiol treatment induces multiple canalicular membrane transport alterations in rat liver. J. Clin. Invest. 91: 2714-2720, 1993.
6. BURKMAN R.: Lipid and lipoprotein change in relation to oral contraception and hormonal replacement therapy. Fertil. Steril. 49: 39-50, 1988.
7. BURSTONE M.: The relationship between fixation and techniques for the histochemical localization of hydrolytic enzymes. J. Histochem. Cytochem. 6: 322-339, 1958.
8. CZEKAJ P., NOWACZYK-DURA G.: Effects of different synthetic steroid combinations on the activity of mixed function oxidase system and on the morphology of rat liver. Exp. Tox. Pathol. 48 (Suppl. II): 82-87, 1996.
9. CZEKAJ P., PLEWKA A., KAMINSKI M., NOWACZYK-DURA G., PAWLICKI K., WIELGUS-SERAFINSKA E: Daily and circadian rhythms in the activity of mixed function oxidases system in rats of different age. Biol. Rhythm. Res. 25: 67-75, 1994.
10. CZEKAJ P., PLEWKA A.: Comparison of the activity of hepatic and renal mixed function oxidases system in different periods of postnatal life in rats. Folia Med. Cracov. 3: 225-236, 1990 (in Polish).
11. DALY L., BONNAR J.: Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis and platelets. Am. J. Obstet. Gynecol. 163: 430-437, 1990.
12. DORFLINGER L.: Relative potency of progestins used in oral contraceptives. Contraception. 31: 557-570, 1985.
13. FABER E., STERNBERG W., DUNLOP G.: Histochemical localization of specific enzymes. I. Tetrazolicum stains for diphosphopyridine nucleotide diaphorase and triphosphopyridine nucleodiaphorase. J. Histochem. Cytochem. 4: 254-259, 1956.
14. FOTHERBY K.: Oral contraceptives, lipids and cardiovascular diesease. Contraception 31: 367-394, 1985.
15. FOTHERBY K.: Clinical experience and pharmacological effects of an oral contraceptive containing 20 mg oestrogen. Contraception 46: 477-488, 1992.
16. FU D., HORNICK C.: Modulation of lipid metabolism at rat hepatic subcellular sites by female sex hormones. Biochim. Biophys. Acta 1254: 267-273, 1995.
17. GASPARD U., BURET J., GILLAIN D.: Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 31: 395-408, 1985.
18. GOMORI G.: Principle and practice. In: Microscopic Histochemistry. The University of Chicago Press, 1953, pp 137-224.
19. GONZALEZ A., OBERLEY T., LI J.: Morphological and immunohistochemical studies of the estrogen-induced Syrian hamster renal tumor: probable cell origin. Cancer Res. 49: 1020-1028, 1989.
20. KJAER A., LEBECH A., BORGGAARD B., REFN H., PEDERSEN L., SCHIERUP L., BREMMELGAARD A.: Lipid metabolism and coagulation of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 40: 665-673, 1989.
21. KULCSAR A., KULCSAR-GERGELY J.: Administration of progesterone and progestogens in chronical liver injury. Drug Res. 29: 1-5, 1979.
22. KOSE K., DOGAN P., OZESMI C.: The effect of contraceptive steroids on hepatic cholesterol metabolism in female rats. Biochem. Mol. Biol. Int. 30: 237-243, 1993.
23. KUHL H.: Ovulationshemmer: Die Bedeutung der Oestrogendosis. Geburtsh. Frauenheilk, 12: 910-922, 1990.
24. KUNG A., MA J., WONG V., LI D., NG M., WANG C., LAN K., YOUNG R., MA H.: Glucose and lipd metabolism with triphasic oral contraceptives in women with history of gestational diabetes. Contraception. 35: 257-264, 1987.
25. LAYDE P.: Oral contraception study. Lancet. 17: 541-546, 1981.
26. LOPEZ DEL PINO V., LARUSSO N.: Dissociation of bile flow and biliary lipid secretion from biliary lysosomal enzyme output in experimental cholestasis. J. Lipid. Res. 22: 229-235, 1981.
27. MARTUCCI C., FISHMAN J.: P450 enzymes of estrogen metabolism. Pharmacol. Ther. 57: 237-257, 1993.
28. McKINNON M., SUTHERLAND E., SIMON F.: Effect of ethinylestradiol on hepatic microsomal proteins and the turnover of cytochrome P-450. J. Lab. Clin. Med. 90: 1096-1100, 1977.
29. McQUEEN E.: Hormonal steroid contraceptives: further review of adverse reactions. Drugs 16: 322-330, 1978.
30. NACHLAS M., SOU H., DE SOUZA E., CHENG C., SELIGMAN A.: Cytochemical demonstration of succinic dehydrogenase by the use of a new p-nitrophenyl substituent ditetrazole. J. Histochem. Cytochem. 5: 420-436, 1957.
31. NORRIS L., BONNAR J.: Effect of oestrogen dose on whole blood platelet activation in women taking new low dose oral contraceptives. Thromb. Haemost. 72: 926-930, 1994.
32. NORRIS L., BONNAR J.: The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br. J. Obstet. Gynaecol. 103: 261-267, 1996.
33. NOWACZYK-DURA G., CISZKOWA V.: The influence of Trisiston on morphology and histoenzymic activity of the rat liver. Ann. Acad. Med. Siles. 23: 55-70, 1991 (in Polish).
34. OBERLEY T., GONZALEZ A., LAUCHNER L., OBERLEY L., LI J.: Characterization of early kidney lesions in estrogen-induced tumors in the Syrian hamster. Cancer Res. 51: 1922-1929, 1991.
35. PEARSE A.: Histochemistry: Theoretical and Applied. Churchill J. Ltd., London, 1961, pp. 167-178.
36. PEREZ V., GORODISH S., DE MARTIRE J., NICHOLSON R., DI-PAOLA G.: Oral contraceptives: long-term use produces fine structural changes in liver mitochondria. Science 165: 805-807, 1969.
37. RAMOS R., APELO R., OSTERIA T., VILAR E.: A comparative analysis of three different dose combinations of oral contraceptives. Contraception 39: 165-177, 1989.
38. REIMER L.: Elektronmikroskopische Untersuchungs- und Preparationsmethoden. Springer Verlag, Berlin, 1967.
39. RUSH G., SMITH J., NEWTON J., HOOK J.: Chemically induced nephrotoxicity: role of metabolic activation. CRC Crit. Rev. Toxicol. 13: 99-160, 1984.
40. SHENFIELD G.: Oral contraceptives. Are drug interactions of clinical significance? Drug Saf. 9: 21-37, 1993.
41. SKOUBY S., KUHL C., MOLSTED-PEDERSEN L., PETERSEN K., CHRISTENSEN M.: Triphasic oral contraception: metabolic effects in normal women and those with previous gestational diabetes. Am. J. Obstet Gynecol. 153: 495-501, 1985.
42. SPELLACY W., ELLINGSON A., TSIBRIS J.: The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during one year of use. Fertil. Steril. 51: 71-74, 1989.
43. STANCZYK F., ROY S.: Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception 42: 67-96, 1990.
44. TYRER L.: Oral contraceptive practice. In: Fertility Control. S. CORSON, L. DERMAN, L. TYRER (eds), Little Brown and Co., Boston, 1985, pp. 171-187.
45. VAN DYKE R., ROOT K.: Ethinyl estradiol decreases acidification of rat liver endocytic vesicles. Hepatology 18: 604-613, 1993.
46. WACHSTEIN M., MEISEL E.: On the histochemical demonstration of glucose-6-phosphatase. J. Histochem. Cytochem. 4: 592-596, 1956.
47. WACHSTEIN M., MEISEL E.: Histochemistry of hepatic phosphatases at physiological pH with special reference to the demonstration bile canaliculi. Ann. J. Clin. Pathol. 27: 12-23, 1957.
48. WYNN V., GODSLAND I.: Effects of oral contraceptives on carbohydrate metabolism. J. Reprod. Med. 31: 892-897, 1986.
49. ZAKI K., RTZK M., KIRA L., NOUR H., GUORGUIS R.: Studies on the effects of ethinyl estradiol and norethisterone acetate on the adrenal cortex and some other tissues in the rat. Endocrinologie 73: 66-74, 1979.
50. ZHU B., ROY D., LIEHR J.: The carcinogenic activity of ethinyl estrogens is determined by both their hormonal characteristics and their conversion to catechol metabolites. Endocrinology 132: 577-583, 1993.